(Q34015113)

30 July 2017

1 reference

title

Developing new antiviral agents for influenza treatment: what does the future hold? (English)

1 reference

30 July 2017

1

Frederick Hayden

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

Clinical Infectious Diseases

30 July 2017

published in

1 reference

30 July 2017

volume

48 Suppl 1

1 reference

30 July 2017

page(s)

S3-13

1 reference

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

30 July 2017

cites work

1 reference

Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide

21 January 2018

1 reference

Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada

21 January 2018

1 reference

Update on avian influenza A (H5N1) virus infection in humans

21 January 2018

1 reference

Treatment of influenza with neuraminidase inhibitors: virological implications

21 January 2018

1 reference

Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine

21 January 2018

1 reference

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

21 January 2018

1 reference

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

21 January 2018

1 reference

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

Recovery of drug-resistant influenza virus from immunocompromised patients: a case series

21 January 2018

1 reference

Avian influenza A (H5N1) infection in humans

21 January 2018

1 reference

Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents

21 January 2018

1 reference

Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors

21 January 2018

1 reference

Oseltamivir resistance during treatment of influenza A (H5N1) infection

21 January 2018

1 reference

Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors

21 January 2018

1 reference

Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

21 January 2018

1 reference

Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study

21 January 2018

1 reference

Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy

21 January 2018

1 reference

Use of Oseltamivir to control influenza complications after bone marrow transplantation

21 January 2018

1 reference

Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants

21 January 2018

1 reference

Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season

21 January 2018

1 reference

A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.

21 January 2018

1 reference

Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.

21 January 2018

1 reference

WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.

21 January 2018

1 reference

Antiviral agents active against influenza A viruses.

21 January 2018

1 reference

Strategies of development of antiviral agents directed against influenza virus replication

21 January 2018

1 reference

Current and future antiviral therapy of severe seasonal and avian influenza

21 January 2018

1 reference

Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques

21 January 2018

1 reference

The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor

21 January 2018

1 reference

Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1)

21 January 2018

1 reference

Anti-influenza virus activity of peramivir in mice with single intramuscular injection

21 January 2018

1 reference

Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen

21 January 2018

1 reference

In vitro and in vivo activities of anti-influenza virus compound T-705.

21 January 2018

1 reference

Mechanism of action of T-705 against influenza virus

21 January 2018

1 reference

Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice

21 January 2018

1 reference

Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

21 January 2018

1 reference

DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.

21 January 2018

1 reference

Combined inhibition of influenza virus reproduction in cell culture using interferon and amantadine

21 January 2018

1 reference

Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus

21 January 2018

1 reference

Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice

21 January 2018

1 reference

Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice

21 January 2018

1 reference

Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro

21 January 2018

1 reference

John F. Enders lecture 2006: antivirals for influenza.

21 January 2018

1 reference

Antivirals for influenza: historical perspectives and lessons learned

21 January 2018

1 reference

Oral ribavirin treatment of influenza A and B.

21 January 2018

1 reference

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

21 January 2018

1 reference

Antiviral Treatment for Patients Hospitalized with Severe Influenza Infection May Affect Clinical Outcomes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/591851

1 reference

30 July 2017

1 reference